Skip to Content
Merck
All Photos(4)

Key Documents

SAB4200412

Sigma-Aldrich

Anti-PLAUR/uPAR antibody, Mouse monoclonal

enhanced validation

clone PL231, purified from hybridoma cell culture

Synonym(s):

Anti-CD87, Anti-Plasminogen activator urokinase receptor, Anti-UPAR, Anti-URKR, Monoclonal Anti-PLAUR/uPAR antibody produced in mouse

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

PL231, monoclonal

form

buffered aqueous solution

mol wt

antigen ~55 kDa

species reactivity

monkey, rat, canine, human, mouse

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation

concentration

~1.0 mg/mL

technique(s)

indirect immunofluorescence: suitable
western blot: 4.0-8.0 μg/mL using extracts of HL-60 cells

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... PLAUR(5329)

General description

Plasminogen activator, urokinase receptor (PLAUR) is a well-characterized receptor for matrix-degrading proteases. It is encoded by the gene mapped to human chromosome 19q13.31.

Immunogen

peptide corresponding to a sequence at the C-terminus of human PLAUR/uPAR.

Application

Monoclonal Anti-PLAUR/uPAR antibody produced in mouse has been used in Western blotting (WB).

Biochem/physiol Actions

Plasminogen activator, urokinase receptor (PLAUR) plays a vital role in tumor cell invasion, angiogenesis and metastasis. It acts as a key regulator of cell-surface plasminogen activator. It is implicated in various normal and pathological processes. Elevated expression of the gene has been observed in various types of cancers, including head and neck squamous cell carcinoma (HNSCC). Thus, it is considered as an potent biomarker for targeted imaging or therapy. Upregulated expression of PLAUR leads to the progression of kidney disease in children.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

John H Rossmeisl et al.
OncoTargets and therapy, 10, 2077-2085 (2017-04-27)
The expression of the urokinase plasminogen activator receptor (uPAR), a glycosylphosphatidylinositol-anchored protein family member, and the activity of its ligand, urokinase-type plasminogen activator (uPA), have been associated with the invasive and metastatic potentials of a variety of human brain tumors
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.
Chang H Y, et al.
PLoS Biology, 2(2), 7-7 (2004)
Assignment of the Urokinase-Type Plasminogen Activator Receptor Gene (PLAUR) to Chromosome 1 9q 13.1 -q 13.2
B?rglum A D, et al.
American Journal of Human Genetics, 50(3), 492-492 (1992)
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.
Harris N L E, et al.
Oncogene, 36(30), 4288-4288 (2017)
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model
Christensen A, et al.
Oncotarget, 8(9), 15407-15407 (2017)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service